Cessation of Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis—Clinical Trial of the Year

Дата публикации: 15-07-2026 00:00:00

Can patients with multiple sclerosis (MS) safely discontinue their disease-modifying therapy, even after years of clinical stability? That is the question that was addressed by the DOT-MS trial, which is my pick for trial of the year in 2025.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Serum GFAP Dynamics, Disease Progression, and Therapy Response in MS	0	8.04	03-08-2026
2	Thousands with MS to get “life-changing” drug on NHS to help them walk more freely	0	6.47	22-07-2026
3	Multiple Sclerosis Onset Preceding Epstein-Barr Virus Infection	0	12.53	03-08-2026
4	Sclerosi multipla, la svolta arriva da un farmaco già esistente: può riparare il sistema nervoso	0	4.28	22-01-2026
5	No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma	0	11.26	13-08-2026
6	Scientists think they found two key bacteria that cause MS	5	7	19-07-2026
7	These fat-filled brain cells may be making multiple sclerosis worse	0	7.88	29-06-2026
8	Клинические испытания российского препарата от рака мозга начнутся в 2026 году	0	0	25-09-2025
9	Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer	0	13.41	03-08-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 9.74. Источник: jamanetwork.com.